Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1996-10-28
2000-05-02
Saunders, David
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435 721, 435 724, 435 725, 435 794, 435 795, 435975, 436508, 436811, 5303872, 53038821, 5303891, 536 231, C12Q 168, G01N 33567, G01N 3353, C07K 1628
Patent
active
060570970
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to a marker for pathologies comprising an auto-immune reaction and/or for inflammatory diseases, the antibodies directed against said marker and the antibodies directed against said antibodies.
The present invention relates also to a diagnostic device which comprises said marker and/or said antibodies.
The present invention also relates to a method for obtaining the marker present in an animal cell.
BACKGROUND OF THE INVENTION
Numerous pathologies comprising an auto-immune reaction and inflammatory diseases have an uncertain or unknown etiology and may have a multifactor origin.
Apparently, a disorder or a stimulation of the immune system of patients constitutes an important element of the progression of those diseases or pathologies.
Among the auto-immune diseases, systemic lupus erythematosus disease (SLE) is characterized by numerous biological and clinical signs.
However, SLE is a pathology with several clinical signs which may evolve and/or recover themselves each other (i.e. renal, cardiac, brain damages, . . . ). Therefore, as it exists non common and constant signs for all the patients affected by SLE, it has been proposed that the "diagnostic" of this pathology is now obtained from simultaneous characterization of at least four clinical and/or biological signs related to SLE (Arthritis and Rheumatism, Vol. 25, No 11 (1982), Official Journal of the American Rheumatism Association Section of the Arthritis Foundation).
The table 1 represents the sensitivity and the specificity of several preliminary criteria used for the diagnostic of systemic lupus erythematosus (serological and clinical tests).
TABLE 1 ______________________________________
Comparison of sensitivity and specificity of elements
in the 1982 and 1971 patient database
Sensitivity.sup.1
Specificity.sup.2
Element 1982 1971 1982 1971
______________________________________
Malar rash 101/177 (57) (64) 156/162
(96) (98)
Discoid rash 31/177 (18) (17) 161/162 (99) (99)
Alopecia 99/177 (56) (43) 143/162 (88) (97)
Photosensitivity 76/176 (43) (37) 155/162 (96) (99)
Oral ulcers 47/177 (27) (15) 155/162 (96) (99)
Raynaud's 51/176 (29) (20) 132/162 (81) (99)
Arthritis 152/177 (86) (86) 60/162 (37) .sup. NA.sup.3
Proteinuria 89/177 (50) (61) 148/157 (94) (82)
Urinary casts 64/176 (36) (48) 152/157 (97) (89)
Dementia 11/177 (6) NA 160/162 (99) NA
Seizures 21/177 (12) (13) 160/162 (99) (98)
Coma 8/177 (5) NA 162/162 (100) NA
Psychosis 22/176 (13) (19) 161/162 (99) (95)
Focal neurologic 21/177 (12) (11) 155/161 (96) (92)
Pleurisy 92/177 (52) (60) 144/162 (89) (91)
Pericarditis 31/177 (18) (19) 155/162 (96) (97)
Haemolytic anaemia 31/176 (18) (16) 160/161 (99) (98)
Leucopenia 82/177 (46) (40) 144/161 (89) (94)
Thrombocytopenia 37/177 (21) (11) 160/161 (99) (98)
LE cells 58/79 (73) (92) 46/48 (96) (98)
Sm antibody 34/108 (31) NA 59/62 (95) NA
Serologic test for syphilis 19/129 (15) (12) 80/80 (100) (99)
Renal biopsy 57/69 (83) NA 10/10 (100) NA
Skin biopsy 47/69 (68) NA 13/16 (81) NA
Antinuclear antibody 174/175 (99) NA 68/139 (49) NA
DNA antibody 113/168 (67) NA 84/91 (92) NA
CH50 84/120 (70) NA 33/47 (70) NA
C3 88/137 (64) NA 69/76 (91) NA
C4 65/102 (64) NA 33/51 (65) NA
C2 0/0 NA 0/0 NA
______________________________________
.sup.1 : Sensitivity was determined on the SLE population and is expresse
as the number of patients who were positive over the number of patients i
whom the test was determined. Number in parenthesis indicates percentage.
.sup.2 : Specificity was determined on the control population and is
expressed as the number of patients who were negative or normal over the
number of patients in whom the test was determined.
.sup.3 : NA = data non available
However, in order to improve the diagnostic of said pathology, efforts have been made to develop specific and reliable detection devices on the basis of clinical biology analysis.
The presently used
REFERENCES:
Meinke, W and Goldstein, DA. J. Mol. Biol. 86: 757-773, 1974.
Chan, TM et al. Clin. Exp. Immunol. 91: 110-114, Jan. 1993.
Halpern, R et al. J. Immunol. 133(4): 1852-1856, Oct. 1984.
Rieber, M et al. Biochem. Biophys Res. Comm. 159(3): 1441-1447, Mar. 31, 1989.
Harlow, E and Lane, D. in Antibodies: A Laboratory Manual. Harlow & Lane, eds. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. pp. 186-187, 1988.
Duchateau Jean
Servais Genevieve
Saunders David
Universite Libre De Bruxelles
VanderVegt F. Pierre
LandOfFree
Marker for pathologies comprising an auto-immune reaction and/or does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Marker for pathologies comprising an auto-immune reaction and/or, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Marker for pathologies comprising an auto-immune reaction and/or will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1592692